Primary objective:To assess whether the state of premature immune aging (senescent CD8+ T cells) predicts treatment response to physical endurance intervention therapy in depressed patients. We will compare the mood-beneficial effects of physical…
ID
Source
Brief title
Condition
- Mood disorders and disturbances NEC
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
High and low senescent CD8 T cells (either determined by CD28 negativity or
CD57 positivity), i.e. higher or lower than the mean of the senescent CD8+ T
cells in the total depression group at base-line. Response to treatment will be
analysed via HDRS-17 score improvement and responders and non-responders will
be defined via the 50% improvement in HDRS-17 score
Secondary outcome
Other immune senescence markers
1. High and low number of *senescent* CD4+ T cells in the effector
memory (EM) and effector memory re-expressing CD45RA (EMRA) populations
2. High and low signs of monocyte senescence: Monocyte gene expression
of mitochondrial apoptosis (BAX, BCL10, EGR1, EGR2) and the SASP related gene
TNF
3. High and low signs of the monocyte inflammatory pyroptosis state:
Monocyte gene expression of the inflammatory genes IL-1A, IL-1B, IL-6, CCL20
and TNFAIP3
4. Correlates of high and low signs of the monocyte senescent and
inflammatory state in whole blood material TEMPUS): The gene expression of
amongst others BAX, SERPINE1, TGFBR3, NFATC2, TNFAIP3, FOXP3 and CD8
5. High or low levels of the T cell senescence related growth serum
factor IL-7
6. High or low levels of the inflammaging serum factors hsCRP and IL-6
Background summary
Physical training intervention is hypothesized to alleviate signs of premature
aging of the immune system in mood disorder (MD) patients and has concomitantly
beneficial effects on the depression severity.
The premature immune aging state can predict treatment response to physical
training.
Therefore, MD patients with the most outspoken premature immune aging (i.e.
those with signs in the highest tertile) respond better than those with weak or
absent premature immune aging (i.e. those with signs in the lowest tertile).
The signs used for the definition of premature immune aging are:
1. an increased monocyte apoptotic/SASP gene expression (or a correlate thereof
in a whole blood preparation),
2. a positive CMV antibody status
3. reduced serum levels of IL-7
4. increased serum levels of hsCRP and IL-6.
Study objective
Primary objective:
To assess whether the state of premature immune aging (senescent CD8+ T cells)
predicts treatment response to physical endurance intervention therapy in
depressed patients. We will compare the mood-beneficial effects of physical
endurance training in all depressed patients and in those with high versus
those with low signs of premature aging of the immune system.
Secondary objectives:
To compare the longer term socio-economic beneficial effects of physical
endurance training in all depressed patients and those with high versus those
with low signs of premature aging of the immune system.
To compare the signs of a premature aging of the immune system before and after
physical endurance training in mood disorder patients.
To assess whether the state of chronic inflammation indeed predicts treatment
response to TAU with first-line antidepressants (serotonergic/noradrenergic) in
depressed patients as it did in our previous studies and in the literature. We
will therefore compare the mood-beneficial effects of the first line TAU drugs
in all depressed patients and in those with
a) high versus low levels of hsCRP,
b) high versus low levels of IL-6,
c) high versus low levels of pro-inflammatory monocytes and leukocytes.
To construct easy and clinical applicable (finger prick) assay to measure
immune senescence and chronic inflammation in depressed patients
Study design
We will include 2 groups in this study to assess the role of exercise training
on the immune system in MD. The MD patients will be randomized into 2 groups:
Treatment as usual (TAU) and TAU combined with exercise training.
Intervention
Participants in group 1 will receive treatment as usual (TAU), i.e.
pharmacotherapy plus clinical management.
Participants in group 2 will receive TAU combined with exercise training,
consisting of a cycling exercise. The participants in the exercise groups will
do a cycling exercise of 30 minutes, 3 times every week, during a period of 8
weeks.
In the training program, the Functional Threshold Power (measured with
ergometry) will be used to choose the optimal heart rate range for each
patient. The intensity level will increase from 45-50% to 50-60% in the second
week, to 60-65% in the third week and up to 65-70% from the fifth week on.
These increases are necessary to ensure a high enough intensity.
Study burden and risks
Burden
Baseline measurement (including interview, questionnaires, blooddraw,
ergometry) for patients will take approximately 120 minutes.
End of treatment measurement (including questionnaires, blooddraw, ergometry))
for patients will take approximately 90 minutes.
The follow op meeting for patients will take approximately 60 minutes.
The physical training intervention, for half of the patients, will take 35
minutes, 3 times per week, during 8 weeks.
Risks
We do not expect major safety problems related to the study parameters. During
the blood sample drawing and fitness test qualified study personal will be
present. As the study is conducted in the hospital, participants can receive
medical attention if required.
Benefit
The study provides no benefits for the participating participants.
Hanzeplein 1
Groningen 9700RB
NL
Hanzeplein 1
Groningen 9700RB
NL
Listed location countries
Age
Inclusion criteria
Patients
- A depressive episode in the course of unipolar or bipolar disorder with a
HDRS-17 score >13
- Meets DSM criteria for MDD or BD established by MINI interview.
- Age 18-65 years
- Preferably already on an anti-depressant and/or mood stabilizer apparently
without success
- Signed informed consent, able to understand, speak and write the national
language
Exclusion criteria
- Use of beta blockers or other medication affecting hearth frequency
- Abnormalities on ECG (other than normal sinus rhythm)
- Chronic use of anti-inflammatory drugs
- Existing cancer or history of cancer in the last 5 years (except skin
epidermoid cancer or in-situ cervix cancer)
- Existing or planned pregnancy or lactation
- Schizoaffective disorders, schizophrenia
- Immediate risk for suicidal behavior (3 on HamD-17 rating scale
- Known current uncontrolled systemic disease (e.g. LE, RA).
- Known major uncontrolled metabolic disorder (e.g. diabetes, hyper- or
hypothyroidism, Cushing disease of Addison disease).
- Known other significant uncontrolled somatic/organic/neurological disorder,
such as or diabetes or stroke which may affect mood.
- Current or recent (last 4 weeks) use of somatic medication which may affect
mood or the immune system (e.g. corticoids, anti-inflammatory drugs, immune
suppressive drugs).
- Participation in a study of an investigational drug or device concomitantly
or within 30 days prior to this study
- Patients thought to be unreliable or incapable of complying with the
requirements of the protocol
- Patient is relative of, or staff directly reporting to the investigator
Healthy controls:
- Chronic use of anti-inflammatory drugs
- Existing cancer or history of cancer in the last 5 years (except skin
epidermoid cancer or in-situ cervix cancer)
- Known current uncontrolled systemic disease (e.g. LE, RA).
- Known major uncontrolled metabolic disorder (e.g. diabetes, hyper- or
hypothyroidism, Cushing disease of Addison disease).
- Known other significant uncontrolled somatic/organic/neurological disorder,
such as or diabetes or stroke which may affect mood.
- Current or recent (last 4 weeks) use of somatic medication which may affect
mood or the immune system (e.g. corticoids, anti-inflammatory drugs, immune
suppressive drugs).
- Pregnancy
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
Other | Ingediend bij NTR, nog niet toegewezen. |
CCMO | NL74885.042.20 |